Gonadotropin Releasing Hormone Analogs – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers GnRH analogs for central precocious puberty, endometriosis, endometrial thinning prior to ablation, fertility preservation in pre-menopausal women receiving gonadotoxic chemotherapy, preoperative management of uterine fibroids, and selected adolescent/adult gender dysphoria cases when criteria are met. Coverage requires indication- and drug-specific documentation (diagnostic confirmation such as pubertal LH/GnRH stimulation or bone age, age/prior‑therapy criteria), limits on duration/reauthorization, add-back therapy for certain retreatments, and submission of medical records, labs (LH/estradiol/testosterone), prescriber letters and psychosocial support documentation as applicable.

"Central Precocious Puberty (Fensolvi, Lupron Depot-Ped, Supprelin LA, Triptodur): treatment of central precocious puberty (idiopathic or neurogenic) when criteria are met (see diagnosis/age/confirm..."